Mazdutide Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research
Mazdutide (also known as IBI362 or LY3305677) is a synthetic dual agonist peptide that activates both the GLP-1 receptor and the glucagon receptor simultaneously, making it distinct from single-target GLP-1 drugs like semaglutide. It is in Phase 3 clinical development for obesity, type 2 diabetes, and related metabolic conditions, with completed trials showing up to 20.1% body weight reduction at one year and superior glycemic control versus an active comparator. This guide covers what mazdutide does, how its dual mechanism works, what the Phase 3 trial data shows, dosing ranges from clinical research, its safety profile, and how it compares to approved GLP-1 class agents.
